NCT07455110 (BR Male) is a clinical trial of structured Interview in Male Breast Cancer, sponsored by Helios University Hospital Wuppertal.

Who is sponsoring NCT07455110?

NCT07455110 is sponsored by Helios University Hospital Wuppertal.

What drugs are being tested in NCT07455110?

Interventions in NCT07455110: structured Interview.

What condition does NCT07455110 study?

NCT07455110 studies Male Breast Cancer, Quality of Life, Breast Cancer.

Is NCT07455110 still recruiting?

NCT07455110 is currently completed. Last updated 27 March 2026.

Last reviewed 2026-03-27 · How we verify

NCT07455110: BR Male

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

EORTC Quality of Life Measurement in Males With Breast Cancer

Completed Last updated 27 March 2026

What this trial tests

trial testing structured Interview in Male Breast Cancer in 65 participants. Completed in 31 March 2023.

Timeline

1 November 2019

Primary endpoint
20 March 2023

31 March 2023

Quick facts

Lead sponsor	Helios University Hospital Wuppertal
Status	Completed
Study type	OBSERVATIONAL
Enrollment	65
Start date	1 November 2019
Primary completion	20 March 2023
Estimated completion	31 March 2023
Sites	1 location across Germany

Drugs / interventions tested

structured Interview

Conditions studied

Male Breast Cancer — all drugs for Male Breast Cancer →
Quality of Life — all drugs for Quality of Life →
Breast Cancer — all drugs for Breast Cancer →

Sponsor

Helios University Hospital Wuppertal

Who can join

18 and older, male only, with Male Breast Cancer or Quality of Life. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Around 1% of all new cases of breast cancer (BC) diagnosed annually occur in men. Most research to date has focused on female breast cancer (FBC). So what is known about breast cancer in men has been mostly derived from the research and treatment of FBC. Comprehensive, prospective data about Quality of life in men treated for BC is lacking. Therefore, a validated worldwide questionnaire for male BC will be developed.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Male Breast Cancer

Currently open trials in the same condition.

NCT05501704 — ETHAN - ET for Male BC · Phase 2 · recruiting

Other Helios University Hospital Wuppertal trials

Trials by the same sponsor.

NCT05464472 — Impact of Transcatheter Aortic Valve Implantation (TAVI) on Cognitive Functions · unknown
NCT04018235 — Psychometric Properties of the Updated Module on Assessing Quality of Life of Patients With Breast Cancer · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07455110 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Helios University Hospital Wuppertal
Last refreshed: 27 March 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07455110.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing